Peripheral Neuropathy Trial, Recruiting NCT06197165 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT06197165
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People diagnosed with one of these types of amyloidosis: transthyretin amyloidosis caused by a genetic mutation (hereditary TTR), transthyretin amyloidosis not caused by a mutation (wild-type TTR), or light chain amyloidosis (AL)
  • People who are members of a French social security scheme (as a member or a dependent), not including AME (state medical aid)
  • People who have given written agreement to take part in the trial
  • People who score 3 or higher on at least one symptom (such as breathlessness, digestive problems, nausea, pain, anxiety, or depression) on a standard symptom questionnaire called the EESE-R
  • People whose overall score on the EESE-R questionnaire is 10 or higher

Who may not be able to join:

  • People who experience a significant drop in blood pressure when standing up (orthostatic hypotension)
  • People who have a form of amyloidosis that causes fragile, blistering skin (bullous amyloidosis)
  • People who have previously received Shiatsu (a type of pressure-point massage) treatment
  • People who are not able to sit upright on their own
  • People who are not able to travel independently from home to the hospital
  • People who are currently taking part in another interventional research study, or who are still within a required waiting period after a previous study
  • People who are known to be pregnant or breastfeeding
  • People who are under legal guardianship at the time of joining the trial
  • People who are covered under AME (French state medical aid)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 00 33 6 35 37 61 63

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
12 March 2024
Est. completion
12 April 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

EESE-R (ESAS) TOTAL SYMPTOM SCORE AT 48 HOURS AFTER THIRD SHIATSU SESSION

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov